INVESTSUD reposted this
At INVESTSUD, we are delighted to announce the closing of the Series A financing of one of our portfolio companies, atbtherapeutics, raising €54 million 👏 to accelerate the development of its breakthrough therapeutic antibody pipeline derived from its proprietary ATBioFarm platform 🦄. After a "go/no go" financing 5 years ago, a pre-seed equity round and 3 consecutive "bridge" loans supported by the historical investors (*), the company is now backed by a syndicate of international investors (**) led by EQT Life Sciences and MRL Ventures Fund LLC, underlining once again the potential of ATB's technology for the benefit of patients. 🙏 This journey would not have been possible without a fantastic team 💪 and a no less fantastic management team who have now learned in detail all the variations of the PERSEVERANCE and RESILIENCE’s concept 😉 . Warm congratulations to Bertrand Magy (CEO), Max Houry (CSO), Philippe Vandeput (CBO) and Ludwig Camusot (co-Founder) ... you rock guys !!! (*) historical investors : INVESTSUD, Noshaq, Fondation Fournier Majoie, Luxembourg Développement, BAs. (**) series A investors : EQT Life Sciences (John de Koning), MRL Ventures Fund LLC (Karin Kleinhans), V-Bio Ventures, VIVES Partners, SFPIM, Wallonie Entreprendre, Sambrinvest, and existing investors.
ATB Therapeutics raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development ATB Therapeutics is thrilled to announce the successful closing of its Series A financing round for a total of €54 Million. The financing was co-led by top-tier investors EQT Life Sciences and MRL Ventures Fund LLC, (corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA) alongside contributions from V-Bio Ventures, VIVES Partners , the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and existing investors. The amount raised underlines the pioneering and innovative nature of ATB’s years of work in developing a research platform with the potential to create groundbreaking medicines for cancer and autoimmune disease patients. The current capital increase will allow ATB to expand and enhance its state-of-the-art platform as well as to accelerate development of its unique "weaponized" antibodies. ATB's research and development operations will be further extended to Ghent and will expand in Marche-en-Famenne, where the Company is also setting up a cutting-edge pilot manufacturing facility. We would like to express our sincere gratitude to our new investors for their trust in our team and technology, as well as to our long-standing investors (INVESTSUD, Noshaq, LUXEMBOURG DEVELOPPEMENT, Fournier-Majoie Foundation) and the Région Wallonne (Service public de Wallonie) for their ongoing and invaluable support throughout the years. Finally, we are proud of our amazing team at ATB Therapeutics and want to thank them for their relentless efforts every day as they truly make the difference! #SeriesA, #BiotechInnovation, #AutoimmuneDiseases, #BiotechInvestment, #ATBTherapeutics, #BelgianBiotech, atbtherapeutics